Moderna Set to Replace Warner Bros. Discovery on Nasdaq 100
Moderna will join the Nasdaq 100 index, taking the spot vacated by Warner Bros. Discovery in the latest quarterly reshuffle.
Moderna is set to replace Warner Bros. Discovery on the Nasdaq 100 index, according to a report from All News, marking a notable shift in the composition of one of Wall Street's most closely tracked benchmarks.
The Nasdaq 100 tracks the 100 largest non-financial companies listed on the Nasdaq exchange and serves as the basis for widely held investment products, including the Invesco QQQ ETF. Changes to the index's composition can trigger significant buying and selling activity from funds that passively track it.
Read more Global Bond Selloff Deepens as Trump Renews Fed Chair Attacks →
Moderna's inclusion signals continued investor recognition of the biotech sector's scale within the broader technology-oriented index. The company rose to prominence during the COVID-19 pandemic as a leading mRNA vaccine developer and has since pursued a broader pipeline of mRNA-based therapeutics.
Warner Bros. Discovery, the media and entertainment conglomerate formed from the 2022 merger of WarnerMedia and Discovery, will exit the index. The company has faced persistent challenges related to streaming competition and a substantial debt load inherited from its merger.
Index reconstitutions of this kind are routine but consequential, often resulting in sharp price moves for both the incoming and outgoing components as institutional funds rebalance their holdings to reflect the updated benchmark. Continue reading at All News.
